Organon backing satisfies Danish startup's funding needs for a new non-hormonal contraceptive
A new deal with US-based Organon, valued at as much as USD 370m, is enough for two founders to retain ownership of women’s health firm Cirqle Biomedical. No longer lacking funding, they can continue developing a non-hormonal contraceptive candidate.
by Ulrich Quistgaard, translated by daniel pedersen and catherine brett
The two people behind Danish upstart Cirqle Biomedical, which is focused on women’s health, now have better future prospects after inking a partnership deal with US-based Organon last week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
